SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Yazdani Butt, A.
Right arrow Articles by Higenbottam, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yazdani Butt, A.
Right arrow Articles by Higenbottam, T. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In Vitro Pulmonary Vasorelaxant Effect of the Phosphodiesterase Inhibitor Enoximone

A. Yazdani Butt

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

A. Tuan Dinh-Xuan

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

Joanna Pepke-Zaba

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

George Cremona

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

Colin A. Clelland

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

Timothy W. Higenbottam

Department of Respiratory Physiology, Papworth Hospital, Cambridge, England

Enoximone is a phosphodiesterase inhibitor that has both positive inotropic and systemic vasorelaxant activities. The latter are mediated by an increase in vascular smooth muscle concentration of cyclic 3'5' guanosine monophosphate. However, the effect of enoximone on pulmonary vasoreactivity is not estab lished. The authors, therefore, have studied its effect on endothelium-depend ent relaxation mediated by the endothelium-derived relaxing factor nitric oxide (NO), as well as endothelium-independent relaxation of isolated porcine pulmo nary arteries.

Enoximone (10-7 to 10-4 M) caused a dose-dependent relaxation in all pulmo nary arterial rings. This relaxation neither required the presence of the endo thelium nor was affected by the addition of the inhibitor of NO synthase {omega}-nitro-L-arginine methyl ester (10-4 M). Also, the vasorelaxant response of the rings to the endothelium-dependent vasodilator adenosine diphosphate (10-10 to 10-5 M) was not affected by pretreatment with enoximone.

The authors conclude that enoximone is a potent vasodilator that relaxes pulmonary vascular rings through mechanisms independent of the endothe lium. This endothelium-independent vasodilatory effect of enoximone makes it a potentially valuable drug for the treatment of pulmonary hypertension. This particularly applies to diseases in man where NO production by the endothelial cells is impaired.

Angiology, Vol. 44, No. 4, 289-294 (1993)
DOI: 10.1177/000331979304400404


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement